| Identification | Back Directory | [Name]
Tavilermide | [CAS]
263251-78-1 | [Synonyms]
Tavilermide
Glycine, N-(2-hydroxy-5-nitrobenzoyl)-L-α-glutamyl-L-lysyl-L-homoseryl-, cyclic (1→3)-ether
3-((4S,7S,10S)-7-(4-aminobutyl)-4-((carboxymethyl)carbamoyl)-14-nitro-6,9,12-trioxo-3,4,5,6,7,8,9,10,11,12-decahydro-2H-benzo[b][1,5,8,11]oxatriazacyclotetradecin-10-yl)propanoic acid(WXG02263) | [Molecular Formula]
C24H32N6O11 | [MDL Number]
MFCD30533429 | [MOL File]
263251-78-1.mol | [Molecular Weight]
580.54 |
| Chemical Properties | Back Directory | [Boiling point ]
1122.4±65.0 °C(Predicted) | [density ]
1.341±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
3.59±0.10(Predicted) | [color ]
White to off-white | [Water Solubility ]
Water : 5 mg/mL (8.61 mM; adjust pH to 3-4 with HCl) |
| Hazard Information | Back Directory | [Biological Activity]
Tavilermide is a selective TrkA partial agonist. | [in vitro]
Tavilermide (MIM-D3) is a tyrosine kinase TrkA receptor agonist, which can be used to treat dry eye. Tavilermide is a proteolytically stable, cyclic peptidomimetic that has been shown to be a partial TrkA receptor agonist. Tavilermide demonstrates activities similar to NGF (but does not bind to the p75NTR receptor) and can potentiate the effects of suboptimal concentrations of NGF. | [target]
| [storage]
Store at -20°C |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|